Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | TAF1 | P21675 | 1/20 | 0.31 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19657130 | 0.87 | ALDH1A1 (0.33) | ADORA2B | |
| SCHEMBL19663716 | 0.83 | GRM2 (0.32) | PDE4AADORA2AADORA2BPDE4BPDE4C | |
| SCHEMBL24363723 | 0.81 | PDE4A (0.31) | PDE4AADORA2AADORA2BPDE4BPDE4C | |
| SCHEMBL19657286 | 0.79 | CECR2 (0.33) | BRD4TAF1CECR2BRD9 | |
| SCHEMBL17749850 | 0.71 | BRD4 (0.41) | BRD4 | |
| SCHEMBL24363724 | 0.69 | CECR2 (0.52) | BRD4TAF1CECR2BRD9 | |
| SCHEMBL19663854 | 0.69 | — | — | |
| SCHEMBL17758546 | 0.59 | CA1 (0.42) | BRD4 | |
| SCHEMBL24136365 | 0.58 | BRD9 (0.41) | BRD4TAF1CECR2BRD9 | |
| SCHEMBL29025444 | 0.57 | LMNA (0.46) | PDE4AADORA2AADORA2BPDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183009-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | PDE4A 586/4885ADORA2A 3759/4885ADORA2B 2906/4885 |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | PDE4A 586/4885ADORA2A 3759/4885ADORA2B 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.